Additional file 1 of Nitrophenylpiperazine derivatives as novel tyrosinase inhibitors: design, synthesis, and in silico evaluations

Additional file 1: The Supplementary Information file contains NMR spectra

Additional file 1 of Amino-7,8-dihydro-4H-chromenone derivatives as potential inhibitors of acetylcholinesterase and butyrylcholinesterase for Alzheimer’s disease management; in vitro and in silico study

Additional file 1. Fig. S1. 1H NMR spectrum of product 4c. Fig. S2. 13CNMR spectrum of product 4c. Fig. S3. 1H NMR spectrum of product 4d. Fig. S4. 13CNMR spectrum of product 4d. Fig. S5. 1H NMR spectrum of product 4e. Fig. S6. 13CNMR spectrum of product 4e. Fig. S7. 1H NMR spectrum of product 4f. Fig. S8. 13CNMR spectrum of product 4f. Fig. S9. 1H NMR spectrum of product 4g. Fig. S10. 13CNMR spectrum of product 4g. Fig. S11. 1H NMR spectrum of product 4h. Fig. S12. 13CNMR spectrum of product 4h. Fig. S13. 1H NMR spectrum of product 4i. Fig. S14. 13CNMR spectrum of product 4i. Fig. S15. 1H NMR spectrum of product 4j. Fig. S16. 13CNMR spectrum of product 4j. Fig. S17. 1H NMR spectrum of product 4k. Fig. S18. 13CNMR spectrum of product 4k. Fig. S19. 1H NMR spectrum of product 4l. Fig. S20. 13CNMR spectrum of product 4l. Fig. S21. 1H NMR spectrum of product 4m. Fig. S22. 13CNMR spectrum of product 4

Additional file 1 of Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitors

Additional file 1: Figure S1. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-phenylacetamide (7a). Figure S2. N-(2-fluorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7b). Figure S3. N-(4-fluorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7c). Figure S4. N-(2-chlorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7d). Figure S5. N-(3-chlorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7e). Figure S6. N-(4-chlorophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7f). Figure S7. N-(4-bromophenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7g). Figure S8. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(o-tolyl)acetamide (7 h). Figure S9. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(p-tolyl)acetamide (7i). Figure S10. N-(2,6-dimethylphenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7j). Figure S11. N-(4-ethylphenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7k). Figure S12. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(4-methoxyphenyl)acetamide (7 l). Figure S13. N-(4-hydroxyphenyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7m). Figure S14. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(4-nitrophenyl)acetamide (7n). Figure S15. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(naphthalen-2-yl)acetamide (7o). Figure S16. 2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)-N-(4-methylbenzyl)acetamide (7p). Figure S17. N-(4-fluorobenzyl)-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7q). Figure S18. N-benzyl-2-(2-methoxy-4-(4-oxo-3,4-dihydroquinazolin-2-yl)phenoxy)acetamide (7r)